Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2017 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. The question asks for a specific posture: management speaks about counterparties' business as part of its own, the company is already inside that growth, and the counterparties' trajectory is early and large relative to the company. Let's analyze the transcript. The call covers UnitedHealth Group's Q4 2017 earnings. Management discusses various segments: Optum, UnitedHealthcare, etc. They talk about growth in Medicare Advantage, Medicaid, international expansion, OptumCare, etc. Key points: They mention growth in serving more people, new contracts, acquisitions like DaVita Medical Group and Banmedica. They talk about their own initiatives, investments, and strategies. They mention customer retention and new business. But the question specifically asks: does management explain where the company is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of the forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories? We need to see if management describes, for example, a specific customer's expansion plans, or a partner's rollout, and says that will drive their business. Instead, management talks about their own actions: they are entering new markets, they have a pipeline, they are investing. They mention "we expect to add Banmedica" and "we expect to close" etc. They talk about their own growth in membership. They do mention "West Virginia became the first state to engage Optum to integrate program eligibility" - that is a specific counterparty, but it's a new engagement, not an existing one scaling. They mention "Healthcare transformation alliance relationship is off to an excellent start with 10 companies selecting OptumRx" - that is new customers, not existing ones scaling. They talk about "Quest Diagnostic" implementation completed, but that's a completed implementation, not a forward trajectory.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.